Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy KemPharm stock

Own KemPharm stock in just a few minutes.

KemPharm is currently traded as an over-the-counter (OTC) stock, which means that some shares are available, but not easy to access. The company plans to list on the Nasdaq, which will make it easy to buy shares from any major brokerage account. Here's how.

How to buy shares in KemPharm

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KMPH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

KemPharm share price

Use our graph to track the performance of KMPH stocks over time.

KemPharm shares at a glance

Information last updated 2021-04-30.
52-week range$1.94 - $22.08
50-day moving average $9.67
200-day moving average $10.38
Wall St. target price$19.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.73

Buy KemPharm shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy KemPharm stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

KemPharm financials

Revenue TTM $13.3 million
Gross profit TTM $12 million
Return on assets TTM -27.52%
Return on equity TTM 0%
Profit margin -96.03%
Book value $-2.83
Market capitalisation $277 million

TTM: trailing 12 months

Shorting KemPharm shares

There are currently 3.3 million KemPharm shares held short by investors – that's known as KemPharm's "short interest". This figure is 13.3% up from 2.9 million last month.

There are a few different ways that this level of interest in shorting KemPharm shares can be evaluated.

KemPharm's "short interest ratio" (SIR)

KemPharm's "short interest ratio" (SIR) is the quantity of KemPharm shares currently shorted divided by the average quantity of KemPharm shares traded daily (recently around 3.1 million). KemPharm's SIR currently stands at 1.07. In other words for every 100,000 KemPharm shares traded daily on the market, roughly 1070 shares are currently held short.

To gain some more context, you can compare KemPharm's short interest ratio against those of similar companies.

However KemPharm's short interest can also be evaluated against the total number of KemPharm shares, or, against the total number of tradable KemPharm shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case KemPharm's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 KemPharm shares in existence, roughly 120 shares are currently held short) or 0.118% of the tradable shares (for every 100,000 tradable KemPharm shares, roughly 118 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against KemPharm.

Find out more about how you can short KemPharm stock.

KemPharm share dividends

We're not expecting KemPharm to pay a dividend over the next 12 months.

You may also wish to consider:

Have KemPharm's shares ever split?

KemPharm's shares were split on a 1:16 basis on 27 December 2020. So if you had owned 16 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your KemPharm shares – just the quantity. However, indirectly, the new 1500% higher share price could have impacted the market appetite for KemPharm shares which in turn could have impacted KemPharm's share price.

KemPharm share price volatility

Over the last 12 months, KemPharm's shares have ranged in value from as little as $1.936 up to $22.08. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while KemPharm's is 3.3602. This would suggest that KemPharm's shares are significantly more volatile than the average for this exchange and represent a higher risk.

To put KemPharm's beta into context you can compare it against those of similar companies.

KemPharm overview

KemPharm, Inc. , a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia. KemPharm's lead clinical development candidate for the treatment of stimulant use disorder, KP879, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site